title: Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis.
abstract: Experimental autoimmune encephalomyelitis (EAE), induced in Lewis rats by injection of myelin basic protein (MBP) and adjuvant, is a T cell-mediated autoimmune disease. Earlier studies from our laboratory have shown that oral administration of guinea pig MBP before encephalitogenic challenge induces T cell anergy and results in the suppression of clinical signs and CNS histopathologic changes of EAE. In contrast, oral administration of rat MBP did not confer a similar degree of protection. This study was undertaken to determine the tolerogenicity of the synthetic peptide 68-88 derived from guinea pig (GP) MBP and rat MBP. These peptides differ by a single amino acid at position 80. Lewis rats fed GP 68-88 were protected from EAE induced with GP 68-88 or rat 68-88. In contrast, feeding rats 68-88 did not protect the animals from challenge with either peptide. Measurement of the frequency of peptide-reactive Th1 cells showed results consistent with the clinical picture. The in vitro proliferative response was significantly suppressed following oral administration of either whole GP MBP, the GP peptide, or the rat peptide, irrespective of clinical status. These results extend our earlier observation at the whole molecule level that GP but not rat MBP confers oral tolerance. These findings suggest that small structural differences at the amino acid level can produce dramatic differences in clinical outcome, with important implications for the design of multiple sclerosis clinical trials.
authors.affiliation: Department of Medical Microbiology and Immunology, Ohio State University College of Medicine, Columbus 43210, USA.
authors.forename: N H
authors.initials: NH
authors.lastname: Javed
authors.forename: I E
authors.initials: IE
authors.lastname: Gienapp
authors.forename: K L
authors.initials: KL
authors.lastname: Cox
authors.forename: C C
authors.initials: CC
authors.lastname: Whitacre
mesh_terms: D000284:Administration, Oral; D000595:Amino Acid Sequence; D000818:Animals; D001324:Autoantigens / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology* / Q000517:prevention & control; D002478:Cells, Cultured; D003888:Desensitization, Immunologic; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000517:prevention & control; D005260:Female; D006168:Guinea Pigs; D007108:Immune Tolerance; D007376:Interleukin-2 / Q000378:metabolism; D008213:Lymphocyte Activation; D008969:Molecular Sequence Data; D004676:Myelin Basic Protein / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use / Q000633:toxicity; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use / Q000633:toxicity; D051381:Rats; D011917:Rats, Inbred Lew; D013045:Species Specificity; D018417:Th1 Cells / Q000276:immunology* / Q000378:metabolism; D014360:Trypsin Inhibitor, Kunitz Soybean / Q000008:administration & dosage
chemical_list: D001324:Autoantigens; D007376:Interleukin-2; D004676:Myelin Basic Protein; D010446:Peptide Fragments; C079716:myelin basic protein 68-88; D014360:Trypsin Inhibitor, Kunitz Soybean